GlassScriptPhysician profile
Christy Page
NPI 1215212568
$7,012.41
in general payments reported to CMS, 2019-2025
34 companies · $1,626 in 2025
The $1,626 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $112 · 2022: $1,459 · 2023: $1,765 · 2024: $2,050 · 2025: $1,626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,441.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,143.42 | 2022-2025 | |
| Lilly USA, LLC | $942.32 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $911.17 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $744.70 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $616.33 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $569.85 | 2021-2025 | |
| Abbott Laboratories | $309.53 | 2022-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $214.86 | 2022-2025 | Xifaxan |
| Exact Sciences Corporation | $183.38 | 2023-2025 | Cologuard Collection Kit |
| Currax Pharmaceuticals LLC | $135.01 | 2022-2024 | Contrave, Nexlizet, Nexletol |
| Astellas Pharma US INC | $132.68 | 2022-2025 | Veozah |
| Amgen INC. | $111.94 | 2022-2025 | Evenity, Prolia, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.46 | 2021-2024 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $102.10 | 2022-2024 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $96.92 | 2022-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $83.30 | 2022 | |
| Merck Sharp & Dohme LLC | $82.23 | 2022-2024 | Gardasil 9, Gardasil, Capvaxive |
| Otsuka America Pharmaceutical, INC. | $62.41 | 2022-2025 | Rexulti |
| Dynavax Technologies Corporation | $61.61 | 2022-2024 | Heplisav-B |
| Insulet Corporation | $59.28 | 2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $39.75 | 2023 | Gvoke Hypopen |
| Dexcom, INC. | $38.24 | 2022-2024 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $35.44 | 2022 | |
| Axsome Therapeutics, INC. | $29.79 | 2025 | Auvelity |
| Boston Scientific Corporation | $27.08 | 2021 | |
| Phathom Pharmaceuticals, INC. | $25.47 | 2024-2025 | Voquezna |
| Inspire Medical Systems, INC. | $24.46 | 2025 | Inspire |
| Mylan Specialty L.P. | $23.70 | 2023 | Yupelri |
| Sumitomo Pharma America, INC. | $22.54 | 2025 | Gemtesa |
| Sanofi Pasteur INC. | $19.86 | 2022 | |
| Intra-Sana Laboratories | $14.98 | 2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Lundbeck LLC | $14.48 | 2025 | Rexulti |
| Scynexis, INC. | $14.32 | 2022 | |
| Idorsia Pharmaceuticals US INC | $12.80 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christy Page listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.